MSF: New Diabetes Medicines Added to WHO Essential Medicines List
- A critical step toward improving global health outcomes for diabetes is underway, focused on ensuring access to life-saving medications.
- Currently, that principle isn't being realized for many people living with diabetes, notably in low- and middle-income countries.
- Diabetes is a growing global health crisis, and effective management is key to preventing devastating complications.
The Global Fight for Diabetes Care: Why Access to Essential Medicines Matters
A critical step toward improving global health outcomes for diabetes is underway, focused on ensuring access to life-saving medications. When the World Health Association (WHO) adds a medicine to its Essential Medicines List (EML),it’s a powerful signal: this drug is considered vital for public health and should be both affordable and readily available to those who need it.
Currently, that principle isn’t being realized for many people living with diabetes, notably in low- and middle-income countries. Rapid-acting insulin analogues and GLP-1 receptor agonists – medications crucial for managing blood sugar levels – are frequently enough either prohibitively expensive or simply unavailable in regions where organizations like Doctors Without Borders/Médecins Sans Frontières (MSF) operate.
The Impact of Limited Access
Diabetes is a growing global health crisis, and effective management is key to preventing devastating complications. rapid-acting insulins and GLP-1s play a vital role in this management, helping individuals maintain stable blood sugar levels and considerably reducing the risk of long-term health problems like kidney failure, blindness, and nerve damage. These complications, in turn, often require extensive and costly medical care - care that is frequently out of reach for those in resource-limited settings.
the lack of access isn’t simply a medical issue; it’s a matter of equity. People living in low- and middle-income countries deserve the same opportunities to live healthy lives as those in wealthier nations.
What Needs to Happen
The WHO’s EML designation is more than just a recommendation. It’s a call to action for several key stakeholders:
- National Governments: Countries should prioritize the inclusion of these essential medicines in thier national health policies and formularies.
- Pharmaceutical Corporations: Companies have a responsibility to register these medications within the countries where they are needed, facilitating local availability.
- Global Health Organizations: Continued advocacy and support are crucial to drive down prices and improve supply chains.
Addressing this challenge requires a concerted effort to ensure that these vital medications are not considered luxuries, but rather basic components of accessible healthcare for all. The goal, as of September 5, 2025, and beyond, should be to make quality diabetes care a reality, not a privilege.